155 BOVET RD., SUITE 303, SAN MATEO, CA
Sagimet Biosciences Enters Underwriting Agreement for Stock Offering
Investor Presentation
Other Events
Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Executive Compensation Granted to David Happel, Thierry Chauche, and Elizabet...
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. Enters Underwriting Agreement for $164.5M Offering
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence